Contrast injector technology firm Medrad has launched the next generation of its Intego PET radiopharmaceutical infusion system, which features a new design that is 38% smaller and includes enhancements to technologist workflow.
Intego was originally launched in 2008 and has been cleared by the U.S. Food and Drug Administration (FDA) for automated, controlled infusion of F-18 FDG and F-18 sodium fluoride (NaF), the most common PET radiopharmaceuticals used in oncology, according to Medrad.
The company plans to display Intego in June at the annual SNM meeting in San Antonio.
